Conditions: Non-Hodgkin's Lymphoma
Keywords: Mantle Cell Lymphoma Non-Hodgkin's Lymphoma temsirolimus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 101
Healthy volunteers: no

Brief summary:
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: temsirolimus intervention 2: temsirolimus
Intervention descriptions: intervention 1: 175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit intervention 2: 75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit

Protocol document: